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A b s t r a c t
Introduction: Single-shot techniques such as cryoballoon and multipolar phased pulmonary vein ablation catheter (PVAC) are 
an alternative to the point-by-point radiofrequency method for atrial fibrillation (AF) ablation. However, there is a lack of data con-
cerning sequential use of single-shot techniques, that is, for both the index and redo ablation. 
Aim: To assess long-term outcomes of the ‘single-shot techniques only’ AF ablation strategy.
Material and methods: We analyzed all consecutive AF ablations performed over a 10-year period (2009–2019) in a center 
where a ‘single-shot technique only’ principle was followed from the start of the AF ablation program. Kaplan-Meier AF-free survival 
curves were calculated and complications were assessed on the basis of our prospectively maintained database.
Results: A total of 597 patients (62.4 ±12.5 years) with paroxysmal (78.1%) or persistent (21.9%) AF entered the study and 655 
AF ablation procedures were performed. In 96.5% of redos (n = 58) a different technique (mostly PVAC) was used than for the index 
ablation (mostly cryoballoon). The Kaplan-Meier estimates of 1, 2 and 5 years freedom from AF were 78.2%, 69.2%, and 56.0%, for 
the index ablation, and 80.3%, 76.1% and 68.3%, for the redo, respectively. The minor and major complication rates were 8.1%, and 
4.0%, respectively.
Conclusions: An AF ablation program based solely on sequential use of two different single-shot techniques for both index and 
redo procedures is safe and effective. These observations might have important practical implications for new operators/centers 
starting AF ablation programs and for use of single-shot techniques for redo procedures.
Key words: atrial fibrillation ablation, redo ablation, single-shot technique, pulmonary vein ablation catheter, cryoballoon.
S u m m a r y
Long-term effectiveness and safety of an atrial fibrillation (AF) ablation program based on the principle of using only 
“single-shot” technique is reported. This novel AF ablation strategy was based on sequential use of two different single-shot 
techniques. Our results include, the first to date, assessment of efficacy of PVAC (pulmonary vein ablation catheter)-based 
ablation for AF redo procedures and suggest that various single-shot technique types can be successfully combined. These 
observations might have important practical implications for new operators/centers starting AF ablation programs and for 
use of single-shot techniques for redo procedures. 
Introduction
Pulmonary vein (PV) isolation is a standard treatment 
option for patients with symptomatic atrial fibrillation 
(AF). Single-shot ablation techniques such as cryoballoon 
and multielectrode circular catheter emerged as a prac-
tical alternative to the classic point-by-point radiofre-
quency/3-dimensional system based AF ablation meth-
od [1, 2]. Several studies have shown that outcomes of 
cryoballoon ablation, in terms of freedom from AF and 
safety profile, are comparable to point-by-point radiof-
requency ablation [3, 4]. Data concerning multielectrode 
phased radiofrequency ablation using pulmonary vein 
ablation catheter (PVAC, Medtronic) are less robust, al-
though reported outcomes were similar [1]. However, 
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data concerning these two single-shot techniques came 
from centers/operators with substantial prior experi-
ence with radiofrequency/3-dimensional system based 
AF ablation. This might affect the single-shot technique 
outcomes, and the results of these studies might not be 
fully applicable to new centers or operators who want 
to rely solely on single-shot techniques. Moreover, there 
is a  scarcity of data concerning the use of single-shot 
techniques for redo ablation when the index procedure 
was also performed with a single-shot technique, i.e. se-
quential use of two single-shot methods. Together these 
gaps in knowledge might lead to the underutilization of 
single-shot techniques.  
Aim
The aim of this study was to investigate outcomes 
(AF-free survival, redo rate, redo efficacy and complica-
tions) of AF ablation in an electrophysiology laboratory 
where a  ‘single-shot technique only’ principle was fol-
lowed at the start of the AF ablation program, both for 
the index ablation and for all redo procedures.
Material and methods
Study population
This observational study enrolled consecutive pa-
tients with symptomatic paroxysmal, persistent and 
long-standing persistent AF, defined according to the 
Heart Rhythm Society (HRS)/European Heart Rhythm 
Association (EHRA) guidelines, with a  history of failed 
treatment with one or more antiarrhythmic drugs (class 
I or III) [5]. On the basis of our prospectively maintained 
registry of all consecutive PV isolation procedures per-
formed over a 10-year period, from June 2009 to Septem-
ber 2019 (to ensure a minimal follow-up of 6 months) 
we conducted a study analyzing outcomes of AF ablation 
after the index and redo single-shot technique based 
procedures. The study was approved by the institutional 
ethical committee of the Jagiellonian University (number 
1072.6120.70.2020).
Preprocedural management
Transthoracic echocardiography using standard para-
sternal long and short axis views and apical two- and 
four-chamber views was performed within 1 week be-
fore ablation, enabling assessment of left ventricular 
ejection fraction and intracavitary dimensions. The an-
ticoagulation strategy evolved during the study period. 
In the years 2009–2017 patients were anticoagulated 
with warfarin or acenocoumarol – with low-molecular 
weight heparin bridging before/after the procedure. Be-
tween 2017 and 2019, procedures were generally per-
formed with uninterrupted oral anticoagulation (war-
farin/acenocoumarol), while novel oral anticiagulatns 
were stopped shortly before CB ablation (morning dose 
skipped). The presence of left atrial thrombi was exclud-
ed by transesophageal echocardiography within 24 h 
before ablation in every patient. To exclude thrombus the 
left atrial appendage (LAA) was visualized in multiple two-di-
mensional TEE imaging planes. It was achieved by first de-
veloping the mid-esophageal aortic valve short-axis view 
(30–60°) and then anteflexing the transducer and rotating 
the multiplane angle from 0° to 180°. Later, a multi-planar 
LAA reconstruction of 4D volume was prepared.
Ablation procedure
All procedures were performed by one of the two op-
erators (M.J. or T.S.), both without any prior experience 
with PV isolation using the point-by-point radiofrequency 
technique. For the first ablation procedure, a cryoballoon 
was preferably used while for the redo procedures PVAC 
was favored. All ablation procedures were performed un-
der conscious sedation (fentanyl and midazolam bolus-
es). A single transseptal puncture using a Brockenbrough 
needle (BRK-1, St. Jude Medical, St Paul, MN, USA) and 8F 
transseptal sheath (SL-1, St. Jude Medical, St Paul, MN, 
USA) was performed under fluoroscopy using only con-
trast injection to confirm left atrial access. No prior PV 
anatomy assessment was performed; if considered nec-
essary, PV anatomy was assessed with contrast/angiog-
raphy during the procedure. His bundle catheter and cor-
onary sinus catheter were used to facilitate transseptal 
puncture and also for phrenic nerve pacing and electro-
physiological assessment of PV isolation. During the pro-
cedure intravenous heparin was administered to achieve 
an activated clotting time > 350 s; measurements were 
performed every 30–40 min. 
The 28-mm cryoballoon (Medtronic Cryocath, Min-
neapolis, MN, USA) was used in all patients. The proce-
dure generally followed published expert consensus rec-
ommendations [6]. However, the cryoballoon technique 
evolved over the 10-year observation period of this study. 
Notably, the balloon design was changed from cryobal-
loon type 1 (CB1) to cryoballoon type 2 (CB2) to allow 
more uniform cooling and freeze protocols were appro-
priately modified; CB1 was used until November 2012. 
Optimal vein occlusion with total contrast retention, i.e. 
no back flow to the atrium, was aimed for; when this was 
not possible the ‘pull-down’ maneuver or overlapping 
applications were used. On the basis of published data 
freeze time was shortened from 5 mins to 3–4 min for 
left PVs and to 2–3 min for the right PVs and the number 
of applications was decreased from 3 per vein to 1–2 per 
vein. Both the freeze time and number of applications per 
vein were at the operator’s discretion, guided by ‘time to 
effect’, minimal achieved temperature, thaw time, grade 
of the vein occlusion, use of ‘pull-down’ maneuver, the 
perceived arrhythmogenic potential of a particular vein, 
etc. For 226 consecutive patients ablated with CB2 the 
following information was gathered for better group 
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characterization: number of cryoballoon applications per 
vein, total time of all cryoballoon applications per vein, 
minimal temperature achieved at 1 minute in each vein, 
minimal temperature at the end of cryoballoon applica-
tion in each vein, PV entrance block time (“time-to-ef-
fect”) in each vein.
The PVAC is a  steerable, 9F, over-the-wire multielec-
trode circular mapping and ablation catheter that requires 
a  multichannel radiofrequency (RF) generator (GENius; 
Medtronic, USA) in order to deliver synchronous duty-cy-
cled phased unipolar and bipolar RF energy with its mul-
tiple electrodes. Overlapping 60-second RF applications 
were delivered in each PV. Ablation was mostly performed 
in a 2 : 1 bipolar/unipolar mode and switched to a 1 : 1 or 
4 : 1 mode at the operator’s discretion. We followed the 
ablation technique as described by others [1].
Regardless of the single-shot technique and/or pro-
tocol used for the energy application the procedural end-
point both for the index procedure and redo ablation was 
electrical isolation of all PVs. PV isolation was confirmed 
with the sudden disappearance of PV potentials or com-
plete dissociation of PV potentials from atrial electrical 
activity; this was assessed in real time during cryoballoon 
freeze using an inner lumen circular multielectrode cath-
eter (Promap, ProRhythm Inc., Ronkonkoma, NY, USA or 
Achieve, Medtronic Minneapolis, MN, USA). Alternatively, 
when disappearance of PV potentials was not visualized 
in real time during cryoenergy application, PV ostia were 
assessed for PV potentials and conduction block after the 
completion of a freeze-thaw cycle and this was compared 
with electrical activity at this site before cryoballoon ap-
plication (template method). In case of recording suspi-
cious electrical activity beyond the ablation line, pacing 
maneuvers from the coronary sinus, left atrial appendage 
and right atrium were performed to differentiate far-field 
signals from PV potentials and also presence of exit block 
was assessed by pacing from the circular catheter within 
the PV. Because electrograms cannot be assessed during 
the delivery of phased RF current the template method 
combined with diagnostic pacing maneuvers was used 
during all PVAC-based ablation procedures. At the end of 
the procedure patients still in atrial fibrillation were elec-
trically cardioverted, and when considered necessary PV 
isolation was re-assessed.
During ablation in the antra of the right-sided PVs, 
phrenic nerve function was monitored by continuous 
phrenic nerve stimulation in the superior vena cava com-
bined with palpation of the upper abdomen in order 
to assess strength of diaphragmatic contraction. More-
over, in the last 307 patients a rule was adopted to stop 
cryoapplication when the freezing temperature dropped 
below –56°C.
Post-ablation management
Sheaths were usually removed 5 h after the proce-
dure or, occasionally, immediately after the ablation, 
following protamine administration. Oral anticoagula-
tion was started 6 h after sheath removal and contin-
ued for at least 3 months, and according to the CHADS2/
CHA2DS2-VASc scores thereafter. Preprocedural antiar-
rhythmic drugs were usually continued for 1–2 months. 
Some patients with long-persistent AF were treated with 
amiodarone for 3–6 months. 
Follow-up and study endpoints
The analyzed primary endpoint of this study was free-
dom from AF recurrence. AF recurrence was defined as 
the first episode of AF lasting > 30 s diagnosed after the 
blanking period of 3 months. AF had to be documented by 
electrocardiogram (ECG), Holter monitoring or physician 
interpreted intracardiac electrogram from the implanted 
device (event marker data were considered unreliable). 
All patients were advised to have an ECG performed each 
time they experienced palpitations. Holter monitoring 
(24–72 h long) was scheduled after 3 and 6–9 months 
post-ablation and then advised once a year. Additional-
ly, all patients received a  telephone call at the time of 
conducting this study and were asked about symptoms, 
results of ECGs and Holter monitoring. 
Secondary endpoint of this study was freedom from 
acute and long-term complications of AF ablation proce-
dures. Acute (i.e. predischarge) complications were mon-
itored and analyzed prospectively in accordance with the 
HRS/EHRA guidelines, published systematic reviews and 
other studies focused on specific complications of sin-
gle-shot methods [7–12]. Long-term complications were 
determined on the basis of out-patient visits and/or 
final telephone conversation. Major complications were 
defined as any life-threatening situation or any adverse 
event with serious symptoms and/or permanent harm 
and/or requiring interventional treatment.
Following our strategy for redo procedures, a different 
single-shot technique was offered to the patients who 
had documented AF post-index ablation and remained 
symptomatic despite the reintroduction of b-blockers 
and/or class I  antiarrhythmic drugs. The follow-up and 
endpoint assessment after a second PV isolation proce-
dure was performed in the same way as after the index 
ablation.
Statistical analysis
Continuous variables are presented as means and 
standard deviations or medians and upper-lower quartile 
for data with non-normal distribution, while categorical 
variables are presented as numbers and percentages. For 
normality assessment the Shapiro-Wilk test was applied. 
The Kaplan-Meier method was used to estimate the sur-
vival functions for each endpoint. The log-rank test was 
used to compare survival distributions. Statistical analy-
sis was performed in R 3.2. P-values < 0.05 were consid-
ered statistically significant. 
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Results
Studied cohort and procedural characteristics
We have identified 617 consecutive patients who un-
derwent a single-shot technique based isolation of PVs 
in our center during the study period; of these, 20 cases 
were excluded for a number of reasons: prior point-by-
point PV ablation in other institution (n = 17), lack of fol-
low-up data (n = 1), non-AF clinical arrhythmia (n = 1) 
or unrelated death (n = 1). Consequently, 597 patients, 
with a mean age of 57.9 ±10.6 years, were analyzed with 
regard to both study endpoints. The majority of patients 
suffered from paroxysmal atrial fibrillation (78.1%), were 
overweight/obese (83.1%) and had some comorbidities 
(84%); detailed baseline clinical characteristics of this co-
hort are presented in Table I. A total of 655 ablation pro-
cedures were performed. The median fluoroscopy time 
was 16.4 (11.2–25.0) min, median dose-area-product, re-
corded only for the last 267 cases, was 1885 (890–3826) 
cG × cm2. Acute success rate was 98%; in 5 (1.5%) pa-
tients one PV could not be isolated, in 2 (0.5%) patients 
two PVs could not be isolated. Cryoballoon application 
characteristics (number of applications in each vein, min-
imal temperature etc.) for 226 non-selected, consecutive 
patients are presented in Table II.
Index procedure outcomes
For the index procedure cryoballoon (n = 589), or, 
much less frequently, PVAC (n = 8) ablation was per-
formed. The 10-year observation period resulted in 
520 571 patient-days of follow-up. The median number 
of Holter ECG monitoring per patient was 3 (2–5) days; 
additionally 36 patients had data available from the im-
planted device capable of AF detection.
Table I. Baseline characteristics of the study popu-
lation (n = 597)
Parameter
Age [years] 57.9 ±10.6
Male gender 390 (65.3%)
BMI [kg/m2] 29.1 ±4.3
AF type:
Paroxysmal 466 (78.1%)
Persistent 105 (17.6%) 
Long-standing persistent 26 (4.3%)
Duration of AF history [months] 36.0 (18.0–72.0)*
Number of failed antiarrhythmic drugs 1.5 ±0.88
Current/past smoker 172 (28.8%)/38 (6.2%)
Comorbidities:
Hypertension 397 (66.5%)
Diabetes mellitus 76 (12.7%)
Chronic coronary syndrome 60 (10.1%)
Heart failure 27 (4.5%)






-VASc score 1.8 ±1.3
eGFR < 60 ml/min/1.73 m2 63 (10.5%)
Echocardiography:
Left atrial diameter [mm] 42.8 ±5.7
Left ventricular ejection fraction, % 60.3 ±8.6
Left ventricular end-diastolic dimen-
sion [mm]
50.2 ±5.7
*Data presented as median and upper and lower quartile. #Defined as cardio-
myopathy or artificial valve or severe valvular disease or left ventricular ejection 
fraction < 50%. BMI – body mass index, AF – atrial fibrillation, TIA – transient 
ischemic attack, eGFR – estimated glomerular filtration rate. 
Table II. Characteristics of the cryotherapy dosage 
protocol (n = 226)
Parameter Value















Minimal temperature at the end of application [°C]:
LSPV 49.0 ±5.3
LIPV 45.2 ±4.9
RSPV 48.9 ±5.1 
RIPV 47.0 ±5.7 
Time-to-effect (PV entrance block) [s]:
LSPV (61.1%)* 61.1 ±67.3
LIPV (41.6%)* 42.1 ±42.4
RSPV (47.3%)* 43.4 ±24.8
RIPV (29.6%)* 43.9 ±21.2
LSPV – left superior pulmonary vein, LIPV – left inferior pulmonary vein, RSPV  – 
right superior pulmonary vein, RIPV – right inferior pulmonary vein, PV – pulmo-
nary vein. *Percentage of patients in whom it was possible to visualize real-time 
occurrence of pulmonary vein isolation.
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During the blanking period AF was observed in 73 
(12.2%) patients. The primary endpoint (AF recurrence, af-
ter the 3-month blanking period) was met in 197 (33.0%) 
patients. The Kaplan-Meier estimates of 1-, 2- and 5-year 
freedom from AF after the index ablation were: 78.2% 
(95% CI: 74.9–81.6%), 69.2% (95% CI: 65.3–73.3%), 
and 56.0% (95% CI: 50.9–61.6%), respectively. Success 
rate was higher for paroxysmal AF than for persistent/
long-standing persistent AF (Figure 1). The first 68 patients 
were treated with CB1, the rest with CB2. The Kaplan-Mei-
er analysis of survival curves showed a 10% lower long-
term success rate when CB1 vs. CB2 was used (Figure 2).
Redo procedure outcomes
A total of 58 redo procedures were performed includ-
ing 51 PVAC and 7 cryoballoon ablations; in 96.5% of 
cases a different single-shot technique was used for the 
second procedure. A median of 2 (1–3) PVs per patient 
showed reconnection; all PVs were successfully re-isolat-
ed. Redo patients were followed for 67.4 months (119 319 
patient-days) after the re-ablation. AF recurrence after the 
3-month blanking period was observed in 17 (29.3%) pa-
tients. Kaplan-Meier estimates of 1-, 2- and 5-year free-
dom from AF after the redo procedure was 80.3% (95% CI: 
70.4–91.4%), 76.1 (95% CI: 65.5–88.4) and 68.3 (95% CI: 
56.1–83.0), respectively; there was no difference in suc-
cess rate between patients with paroxysmal AF vs. per-
sistent/long-standing persistent AF (Figure 3). 
Post-ablation non-AF left atrial arrhythmias
In 7 patients atypical atrial flutters were observed, 
6 after index ablation and one after re-do ablation. In all 
but one of these patients concurrent AF recurrence was 
also noted. Since these arrhythmias are pathophysiologi-
cally distinct from AF they were treated with RF catheters 
rather than single-shot devices.
Complications
There were no deaths or permanent disabilities. In 
72 (12.1%) patients some complication occurred, in-
cluding major complications in 4.0% of patients. Almost 
all complications occurred after the index ablation. In 
the redo procedures only one complication was noted – 
 0 1 2 3 4 5 6 7 8 9 10
    Time [years]
 Parox
 466 324 203 143 105 71 48 33 13 4
 Persist
 105 54 31 23 19 13 10 4 1 1
  Persist long
 26 16 10 3 1 1 1 1 1 1
Figure 1. The Kaplan-Meier AF-free survival curve 
after the index AF ablation with regard to AF type
 0 1 2 3 4 5 6 7 8 9 10
    Time [years]
 Parox
 41 29 23 20 16 14 12 9 4
 Persist
 15 12 11 9 5 3 1 1
  Persist long
 2 2 1 1 1 1 1
Figure 3. Kaplan-Meier AF-free survival curve af-
ter the redo ablation with regard to the AF type
 0 1 2 3 4 5 6 7 8 9 10
    Time [years]
 CB1 68 45 41 35 34 32 32 32 15 6
 CB2 529 349 203 134 91 53 27 6
Figure 2. The Kaplan-Meier AF-free survival curve 
after the index AF ablation with regard to type of 
cryoballoon used for ablation. CB1 – cryoballoon 
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a persistent phrenic nerve paralysis. The most frequent 
complications were related to thermal phrenic nerve 
injury; these were closely followed by vascular access 
site complications and iatrogenic atrial septal defect 
requiring intervention (septal occluder implantation in 
7 cases and cardiac surgery in 1 case). All complica-
tions, except one permanent phrenic nerve palsy, were 
resolved with appropriate medical treatment. A full list 
of observed complications is listed in Table III. 
Discussion
This study showed the long-term effectiveness and 
safety of the ‘single-shot technique only’ ablation strat-
egy for the management of AF in a large representative 
cohort of patients. The major findings were: 
1)  the sequential use of two different single-shot tech-
niques is effective, resulting in freedom from AF at 
2 years of 74% and 52%, after the index procedure, 
and 73% and 80% after the redo procedure, for par-
oxysmal and persistent atrial fibrillation, respectively;
2)  the PVAC-based method can be successfully used for 
redo AF ablation.
AF-free survival after single-shot technique 
based ablation
With each year of follow-up the percentage of AF-free 
patients falls, likely reflecting both a suboptimal result of 
the index ablation and the natural course/progression of 
the arrhythmia substrate. The reported AF recurrence rate 
at the second year after a  single-shot technique based 
ablation is around 25–50% with moderate differences 
between different tools used (PVAC, cryoballoon, hot-bal-
loon) and very comparable with the point-by-point radiof-
requency current ablation method [1–3, 8, 13]. Our study 
provides a similar recurrence rate after a single procedure 
over the 10 years of follow-up (Kaplan-Meier survival 
curve in Figure 1). The novelty of our results lies in adding 
a new piece of data to the concept that the single-shot 
technique approach is completely equivalent and alterna-
tive to the classic point-by-point radiofrequency method, 
since in the current study such ablation outcomes were 
achieved using solely single-shot techniques and by oper-
ators who never used the classic point-by-point radiofre-
quency, 3D system based ablation method. 
Additionally, the current study corroborates the data 
regarding higher efficacy of CB2 vs. CB1 [14], and ex-
pands it with very long-term follow-up data that show 
10% absolute difference in AF recurrence rates after 5–6 
years (Figure 2).
Overall, 9.7% of patients underwent a redo during the 
study period; this constituted 29.4% of all patients with 
AF recurrence. The redo rate in our study was slightly 
lower than in most cryoballoon ablation studies that re-
ported a 11.8–19.1 re-ablation rate [15–18], albeit similar 
to the rate of 7.8% obtained from the analysis of Swedish 
catheter ablation registry and the Atrial Fibrillation Abla-
tion Long-Term registry of the European Heart Rhythm 
Association [4]. Our novel strategy for redo ablations, 
based on the principle that a different single-shot tech-
nique should be preferred for the second procedure, was 
effective, as freedom from AF after the second procedure 
was high (Figure 2). Such a strategy was employed based 
on the intuitive rationale that a failure of one single-shot 
technique based procedure might indicate that the left 
atrial anatomy was not suitable for the index single-shot 
technique and that using a different single-shot method 
has a higher chances of overcoming this limitation than 
using the same tools again. For example, a too large an-
trum might facilitate poor contact at some parts of the 
balloon perimeter and hence gaps that could be easily 
closed with PVAC using overlapping circular lesions while 
Table III. Complications of single-shot technique 
based ablation observed in the current study
Complications n (%)
Major:
Death related to the procedure 0
Atrioesophageal fistula 0
Symptomatic pulmonary vein stenosis 0
Stroke 1 (0.17)
Transient ischemic attack 1 (0.17)
Tamponade/pericardiocentesis 5 (0.84)
Tamponade requiring surgery 0
Persistent phrenic nerve injury§ 7 (1.17)
Permanent phrenic nerve injury 1 (0.17)
ASD requiring intervention 8 (1.34)
Bleeding requiring blood transfusion 1 (0.17)
Minor:
Vascular access site complications* 9 (1.51)
Pericardial effusion 4 (0.67)
Pericarditis 1 (0.17)




Symptomatic gastroparesis 2 (0.33)
Symptomatic inappropriate sinus tachycardia 3 (0.50)
Other 2 (0.33)
ASD – atrial septal defect, §present after discharge, *including large hematoma, 
arterio-venous fistula and pseudoaneurysm treated conservatively, and deep 
vein thrombosis; #resolved before discharge.
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the balloon might fail again; a small antrum might not 
allow stabilization of the 28 mm balloon, or the PV take-
off angle or orifice shape might not allow good occlusion 
to be achieved or might result in off-axis cryoballoon to 
PV alignment, leading to poor contact of some segments 
with the balloon. When repeating ablation with balloon 
the same problems might repeat themselves, while with 
PVAC such anatomy might not constitute a  problem. 
PVAC-based ablation after cryoballoon ablation for the 
index procedure was the dominant sequence employed 
by us. We are not aware of any study reporting outcomes 
of such an AF ablation strategy.
A  limited number of studies have investigated out-
comes of cryoballoon ablation for redo after the index 
procedure was also performed with a  cryoballoon. We-
stra et al. studied 40 patients who had both the index 
and redo procedure performed with a  cryoballoon and 
reported that at 1 year, 70% of patients were free of re-
current AF [16]. Similarly, Shade et al. used a cryoballoon 
for both the index and redo procedure in 47 patients and 
found that 60% of them had no AF recurrence during 
a  12-month follow-up period [17]. Cryoballoons were 
also used for redo procedures after the index ablation 
was performed with the point-by-point technique with 
76.6–43% of patients reported free from AF recurrence 
after 11–15 months of follow-up [19, 20]. Together, these 
reports suggest that cryoballoons are useful for re-abla-
tion procedures; our data expand these observations to 
the other single-shot technique, namely, the PVAC. To the 
best of our knowledge there are no published data re-
garding the use of PVAC for redo procedures, suggesting 
that PVAC might be underused for this application.
Complications of AF ablation based on  
single-shot techniques 
Several studies focusing on major complications of 
AF ablation using the point-by-point technique have re-
ported complication rates between 3.9% and 4.9% [8, 
9]. The major complication rate seen during ablation 
performed with cryoballoons, PVAC or other single-shot 
techniques seems to be similar or slightly lower, in the 
range of 2–6% [4, 8, 12, 18, 21]. Our current study cor-
roborates these observations and expands it to a setting 
with a  more radical use of single-shot techniques. Of 
note, despite similar percentages, complication profiles 
of single-shot techniques are slightly different than com-
plications of the point-by-point ablation method, and 
might, therefore, be more prone to reporting bias. Some 
complications such as significant iatrogenic atrial septal 
defect, gastroparesis or migraine headaches (observed 
together in 2.7% of patients in the current study) are not 
even mentioned in most papers focusing on complica-
tions of atrial fibrillation using the classic point-by-point 
radiofrequency method. Importantly, the single-shot 
technique based redo strategy used by us was not relat-
ed to an increased percentage of complications; on the 
contrary, there was only a  2% rate of minor complica-
tions during redos. This stands in contrast to the point-
by-point technique, where redo procedures were shown 
to be an independent predictor of major complications 
(odds ratio 3.6) [22].
Limitations
This was a single-center study with a small number 
of operators and related potential referral and treatment 
bias. Moreover, the ablation technique evolved and the 
equipment changed during the study; notably, after the 
initial 68 cases the CB1 was replaced by CB2, which 
resulted in a  higher success rate. Due to the relatively 
small size of the CB1 cohort we believe that this was 
a  minor limitation that we addressed in an additional 
Kaplan-Meier survival analysis. No long-term monitor-
ing was performed in the majority of patients; therefore, 
the AF recurrence rate might have been underestimat-
ed. However, we believe that our monitoring approach 
reflected real life clinical practice.
Conclusions
This study suggests that a  single-shot technique 
based ablation program results in similar effectiveness in 
atrial fibrillation ablation both for index and redo proce-
dures and that the use of various single-shot technique 
types can be combined for a successful AF ablation pro-
gram. These observations might have important practi-
cal implications for new operators/centers starting AF 
ablation programs and also warrant further studies to 
investigate the role of single-shot techniques for redo 
procedures.
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